Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

被引：0

作者：

Bobin, Arthur ^{[1
]}

Hulin, Cyrille ^{[2
]}

Lambert, Jerome ^{[3
]}

Perrot, Aurore ^{[4
]}

Manier, Salomon ^{[5
]}

Montes, Lydia ^{[6
]}

Jaccard, Arnaud ^{[7
]}

Karlin, Lionel ^{[8
]}

Godmer, Pascal ^{[9
]}

Caillot, Denis ^{[10
,11
]}

Chalopin, Thomas ^{[12
]}

Roul, Christophe ^{[13
]}

Mariette, Clara ^{[14
]}

Rigaudeau, Sophie ^{[15
]}

Delaunay, Jacques ^{[16
]}

Dingremont, Claire ^{[17
]}

Santagostino, Alberto ^{[18
]}

Dib, Mamoun ^{[19
]}

Macro, Margaret ^{[20
]}

Tiab, Mourad ^{[21
]}

Laribi, Kamel ^{[22
]}

Petit, Emmanuelle Bourgeois ^{[23
]}

Calmettes, Claire ^{[24
]}

Piocelle, Frederique Orsini ^{[25
]}

Bareau, Benoit ^{[26
]}

Tabrizi, Reza ^{[27
]}

Vincent, Laure ^{[28
]}

Mohty, Mohamad ^{[29
]}

Touzeau, Cyrille ^{[30
]}

Corre, Jill ^{[31
]}

Moreau, Philippe ^{[32
]}

Facon, Thierry ^{[33
]}

Loiseau, Herve Avet ^{[34
]}

Leleu, Xavier ^{[35
,36
]}

机构：

[1] CHU Poitiers, Poitiers, France

[2] Ctr Hosp Univ Bordeaux, Pessac, France

[3] Univ Paris Cite, St Louis Univ Hosp, AP HP, Biostat & Med Informat Dept, Paris, France

[4] Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France

[5] Ctr Hosp Univ Hop Huriez, Lille, France

[6] Ctr Hosp Univ Amiens Picardie, Serv Hematol Clin, Amiens, France

[7] CHU Limoges, Hematol Clin, Hop Dupuytren, Limoges 1, France

[8] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, France

[9] CH Vannes, Vannes, France

[10] Univ Burgundy & France Comte, Univ Hosp INSERM UMR1231, Dijon, France

[11] Univ Burgundy & France Comte, SAPHIIR UMR 1231, Dijon, France

[12] Ctr Hosp Univ Tours, Tours, France

[13] CH La Rochelle, La Rochelle, France

[14] CHU Grenoble, Grenoble, France

[15] CH Versailles, Le Chesnay Rocquencourt, France

[16] Ctr Hosp Univ Nantes, Nantes, France

[17] Ch Tarbes, Tarbes, France

[18] CH Troyes, Troyes, France

[19] CHU Angers, Angers, France

[20] Hop Cote De Nacre, Caen, France

[21] Ctr Hosp Dept, La Roche Sur Yon 9, France

[22] Le Mans Hosp, Hematol Dept, Le Mans, France

[23] CHU Lille, Lille, France

[24] CH Perigueux, Perigueux, France

[25] CH Metz, Metz Tessy, France

[26] Cabinet Med, Rennes, France

[27] CH Mont de Marsan, Mont De Marsan, France

[28] Montpellier Univ, Hosp Ctr, Dept Clin Hematol, Montpellier, France

[29] Hop St Antoine, Paris, France

[30] Ctr Hosp Univ Nantes, Nantes, France

[31] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[32] Univ Hosp Hotel Dieu, Nantes, France

[33] Lille Univ Hosp, Dept Haematol, Lille, France

[34] Univ Hosp Toulouse, IUCT Oncopole, Unite Genom Myelome, Toulouse, France

[35] Serv Hematol & Therapie Cellulaire, Poitiers, France

[36] Univ Poitiers Hosp, INSERM CIC 1042, Poitiers, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185699

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
Bobin, Arthur
Lambert, Jerome
Perrot, Aurore
Manier, Salomon
Montes, Lydia
Jaccard, Arnaud
Karlin, Lionel
Godmer, Pascal
Caillot, Denis
Hulin, Cyrille
Chalopin, Thomas
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Dingremont, Claire
Santagostino, Alberto
Dib, Mamoun
Macro, Margaret
Tiab, Mourad
Laribi, Kamel
Bourgeois-Petit, Emmanuelle
Calmettes, Claire
Orsini, Frederique
Tabrizi, Reza
Vincent, Laure
Mohty, Mohamad
Touzeau, Cyrille
Corre, Jill
Moreau, Philippe
Facon, Thierry
Loiseau, Herve Avet
Leleu, Xavier
BLOOD, 2022, 140 : 4423 - 4425
[2] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Manier, Salomon
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Chretien, Marie Lorraine
Laribi, Karim
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Macro, Margaret
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
[3] High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
Corre, Jill
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Karlin, Lionel
Roussel, Murielle
Bigot, Noemie
Benbrahim, Omar
Allangba, Olivier Thierry
Rey, Philippe
Dorvaux, Veronique
Vignon, Marguerite
Roland, Virginie
Garidi, Reda
Bastie, Jean-Noel
Chretien, Marie-Lorraine
Godet, Sophie
Montes, Lydia
Cherel, Brieuc
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Dingremont, Claire
Roul, Christophe
Richez, Valentine
Mariette, Clara
Rigaudeau, Sophie
Calmettes, Claire
Dib, Mamoun
Tiab, Mourad
Vincent, Laure
Delaunay, Jacques
Marolleau, Jean Pierre
Godmer, Pascal
Frenzel, Laurent
Le Calloch, Ronan
Chalayer, Emilie
Gardeney, Helene
Macro, Margaret
Royer, Bruno
Decaux, Olivier
Arnulf, Bertrand
Merzoug, Karim Belhadj
Touzeau, Cyrille
Mohty, Mohamad
Gontier, Aurelie
Kasmi, Amine
Moreau, Philippe
Facon, Thierry
BLOOD, 2024, 144 : 4756 - 4758
[4] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
Leleu, Xavier P.
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Manier, Salomon
Perrot, Aurore
Jaccard, Arnaud
Montes, Lydia
Karlin, Lionel
Godmer, Pascal
Chalopin, Thomas
Slama, Borhane
Laribi, Kamel
Chretien, Marie-Lorraine
Mohty, Mohamad
Touzeau, Cyrille
Moreau, Philippe
Avet-Loiseau, Herve
Corre, Jill
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Manier, Salomon
Dimopoulos, Meletios-Athanasios
Leleu, Xavier
Moreau, Philippe
Cavo, Michele
Goldschmidt, Hartmut
Orlowski, Robert Z.
Tron, Muriel
Tekle, Christina
Bregeault, Marie-France
Shafer, Andrea
Beksac, Meral
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S290 - S291
[6] Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Usmani, Saad Z.
Facon, Thierry
Hungria, Vania
Bahlis, Nizar J.
Venner, Christopher P.
Braunstein, Marc
Pour, Ludek
Marti, Josep
Basu, Supratik
Cohen, Yael C.
Matsumoto, Morio
Suzuki, Kenshi
Hulin, Cyrille
Grosicki, Sebastian
Legiec, Wojciech
Beksac, Meral
Maiolino, Angelo
Liu, Weiping
Wang, Jianping
Krevvata, Maria
Lopez-Masi, Lorena
Carey, Jodi
Rowe, Melissa
Carson, Robin
Zweegman, Sonja
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S288 - S289
[7] Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
Facon, Thierry
Dimopoulos, Meletios Athanasios
Leleu, Xavier P.
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir I.
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas G.
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert Z.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)
Facon, Thierry
Dimopoulos, Meletios
Leleu, Xavier
Beksac, Meral
Pour, Ludek
Hajek, Roman
Liu, Zhuogang
Minarik, Jiri
Moreau, Philippe
Romejko-Jarosinska, Joanna
Spicka, Ivan
Vorobyev, Vladimir
Cavo, Michele
Goldschmidt, Hartmut
Martin, Thomas
Manier, Salomon
Bregeault, Marie-France
Mace, Sandrine
Berthou, Christelle
Orlowski, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S31 - S31
[9] Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial
D'Agostino, Mattia
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Carlo-Stella, Carmelo
Ronconi, Sonia
Corradini, Paolo
Ballanti, Stelvio
Cellini, Claudia
Falcone, Antonietta Pia
Bringhen, Sara
Offidani, Massimo
Rambaldi, Alessandro
Rota-Scalabrini, Delia
Agazzi, Alberto
Casaluci, Gloria Margiotta
Pietrantuono, Giuseppe
Patriarca, Francesca
Larocca, Alessandra
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S94 - S95
[10] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
Ocio, Enrique M. M.
Bringhen, Sara
Martinez-Lopez, Joaquin
San-Miguel, Jesus
Oliva, Stefania
Rodriguez-Otero, Paula
Le Roux, Nadia
Dong, Yvonne
Doroumian, Severine
Mace, Sandrine
Mateos, Maria-Victoria
HEMASPHERE, 2023, 7 (02):

← 1 2 3 4 5 →